Scancell

Scancell is a clinical-stage biopharmaceutical company that leverages proprietary research findings accumulated over years of studying the human adaptive immune system to develop novel drugs addressing significant unmet needs in the fields of cancer and infectious diseases. The company is utilizing its four technology platforms to develop innovative products: Moditope® and ImmunoBody® for vaccines, and GlyMab® and AvidiMab® for antibodies.